AtaCor Medical
AtaCor Medical is a private medical device company developing an extravascular implantable cardioverter defibrillator lead system that delivers defibrillation and pacing therapies without entering the heart or vasculature, targeting hospitals and cardiac electrophysiology centers.
- Company typePrivate
- Founded2018
- HeadquartersSan Clemente, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AtaCor Medical does
AtaCor Medical, Inc. is a privately held medical device company headquartered in San Clemente, California, developing extravascular implantable cardioverter defibrillator (EV-ICD) technology for the treatment of life-threatening ventricular tachyarrhythmias. Its core product is the EV-ICD Lead System, centered on the proprietary Atala lead and a parasternal delivery system that implants the lead outside the heart and vasculature. The system is designed to deliver defibrillation, antitachycardia pacing (ATP), and shock therapies without transvenous access, eliminating risks such as vascular injury, lead fractures, tricuspid valve damage, and infections associated with conventional transvenous ICDs. Compatibility with commercially available transvenous ICD generators in either lateral or pectoral pocket placements is a deliberate architectural choice to lower adoption friction.
AtaCor is pre-commercial and pre-revenue: its products are explicitly stated to be under development exclusively for investigational use and not approved for sale in any geography. The company is currently running the ASCEND EV Clinical Study in the United States (first permanent implantations in March 2025) with a larger ALARION EV pivotal trial planned for 2026 in collaboration with Abbott. The planned go-to-market model combines direct sales to hospitals and cardiac electrophysiology centers with a co-development and distribution arrangement with Abbott, under which AtaCor's Atala lead is paired with Abbott's ICD system and commercialized through Abbott's established cardiac rhythm management channel.
Leadership is drawn from the Cameron Health, Boston Scientific, Guidant, and Zoll lineage that originally developed the subcutaneous ICD, including CEO Rick Sanghera (70+ CRM patents) and co-founder/VP Regulatory Alan Marcovecchio. Scientific Advisory Board members include principal investigators from the PRAETORIAN trial (Reinoud Knops, Amsterdam UMC) and Mount Sinai's cardiac arrhythmia program (Vivek Reddy). Through October 2025, the company has raised approximately $137 million across four funding rounds, with a $28M Series C in April 2024 led by Arboretum Ventures and a $75M financing in October 2025 earmarked for the FDA pivotal study.
AtaCor Medical firmographics
Firmographics- Name
- AtaCor Medical
- Legal name
- AtaCor Medical, Inc.
- Website
- https://atacor.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AtaCor Medical is a private medical device company developing an extravascular implantable cardioverter defibrillator lead system that delivers defibrillation and pacing therapies without entering the heart or vasculature, targeting hospitals and cardiac electrophysiology centers.
- Ownership category
- akta.pro rank
AtaCor Medical industry classification
Industry- Product category
- Cardiac Rhythm Management Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)
- akta.pro secondary industry
- Electrophysiology (Heart Rhythm) (HLAKABAC)
Keywords
Where AtaCor Medical is headquartered
LocationHeadquarters
- HQ city
- San Clemente
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AtaCor Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Extravascular ICD Lead System: AtaCor Medical generates revenue through the sale of its EV-ICD Lead System (Atala lead and delivery system) to hospitals and cardiac rhythm management centers. The system is designed to be compatible with commercially-available transvenous ICDs, creating a consumable/impantable device revenue model. The company is currently in clinical development stage with products under investigational use only.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
AtaCor Medical product offering
Product offeringCore offering
AtaCor Medical develops and clinically investigates extravascular implantable cardioverter defibrillator (EV-ICD) lead systems designed to deliver defibrillation, antitachycardia pacing (ATP), and shock therapies without placing hardware inside the heart or vasculature. The company's flagship offering, the Atala EV-ICD Lead System, uses a streamlined parasternal delivery approach and is designed for compatibility with commercially-available transvenous ICDs. The products are currently for investigational use only and are not approved for sale in any geography.
Product overview
AtaCor Medical offers a unified extravascular cardiac rhythm management solution centered on its EV-ICD Lead System, which combines the proprietary Atala extravascular lead with a streamlined parasternal delivery system and compatibility with commercially-available transvenous ICDs. The system delivers defibrillation, antitachycardia pacing (ATP), and shock therapies without placing hardware inside the heart or vasculature. The company is also advancing a separate investigational Parasternal EV-ICD System in collaboration with Abbott, planned for a pivotal clinical trial in 2026.
Differentiator
Problem solved
Functional benefit
Brands
- Atala: Investigational extravascular ICD lead designed to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies without hardware placed in the heart or vasculature
- EV-ICD Lead System
- Parasternal EV-ICD System
Products and services
- EV-ICD Lead System AtaCor's flagship extravascular implantable cardioverter defibrillator (EV-ICD) lead system designed to deliver reliable sensing, antitachycardia pacing (ATP), and shock therapies to treat life-threatening ventricular tachyarrhythmias without entering the heart or vascular system. Features the Atala lead implanted via a streamlined parasternal approach, compatible with commercially-available transvenous ICDs for both lateral and pectoral pulse generator pocket placement. Targeted at hospitals and cardiac electrophysiology centers.
- Parasternal EV-ICD System An investigational next-generation extravascular ICD system developed through strategic collaboration with Abbott, pairing AtaCor's Atala lead with Abbott's ICD system. A pivotal clinical trial (ALARION EV Study) is planned for 2026 to evaluate the combined parasternal EV-ICD system. Targeted at cardiac rhythm management hospitals and electrophysiology centers.
Quantifiable outcome
- First permanent implantation of EV-ICD Lead System completed March 2025 as part of ASCEND EV Clinical Study
- +1 more outcomes
Companies that use AtaCor Medical
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
AtaCor Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AtaCor Medical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AbbottcoreAbbott and AtaCor Medical announced collaboration to advance a next-generation extravascular implantable cardioverter defibrillator (EV-ICD) system. AtaCor's investigational Atala lead will be paired with Abbott's ICD system. A pivotal clinical trial (ALARION EV Study) is planned for 2026 to evaluate the investigational parasternal EV-ICD system.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
AtaCor Medical competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Acquired Cameron Health and markets the EMBLEM subcutaneous ICD (S-ICD), the leading extravascular defibrillator today. Direct overlap with AtaCor in extravascular ICD therapy and a likely fast-follower in the EV-ICD-with-ATP category.
- Medtronic: Global leader in CRM with deep transvenous ICD, pacemaker, and CRT-D franchises. Competes in the same hospital call point and has active extravascular/subleadless research that could rival AtaCor's Atala platform.
- BIOTRONIK: Privately held German CRM and electrophysiology device maker with a full line of ICDs and pacemakers. Competes in the same hospital accounts for implantable cardiac devices, including extravascular/subcutaneous programs.
- MicroPort Scientific: Global medical device conglomerate with an active CRM franchise (including ICDs) following its acquisition of LivaNova's CRM business. Competes in the broader implantable CRM market alongside AtaCor's target accounts.
Direct peers
- Abbott: Top-3 CRM incumbent and AtaCor's strategic partner on the ALARION EV Study. Markets its own ICD portfolio and will pair AtaCor's Atala lead with its generator, making Abbott simultaneously collaborator and competitor.
- Cameron Health (historical): Developer of the original S-ICD, founded by many of the same engineers now at AtaCor. Acquired by Boston Scientific in 2012 for approximately $1.4B; serves as the closest analog to AtaCor's positioning and exit trajectory.
Emerging players
- EBR Systems: Developer of leadless pacing technology (WiSE-CRT) for cardiac resynchronization therapy. Comparable as a venture-backed CRM device innovator targeting extravascular or novel-delivery cardiac stimulation approaches.
- Imricor Medical Systems: Focused on MRI-guided cardiac ablation and electrophysiology devices. Comparable as a small-cap, clinical-stage CRM innovator selling into the same EP hospital call point.
- Cala Health: Venture-backed bioelectronic therapy company developing wearable neuromodulation devices for cardiac and neurological conditions. Adjacent peer as a venture-stage electrotherapy innovator in similar reimbursement pathways.
- Cardiac Insight: Developer of wearable ECG/arrhythmia diagnostic devices targeting the same cardiology electrophysiology call points. Adjacent peer as a small-cap cardiac device company selling into hospital EP labs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
AtaCor Medical social profiles
Digital presenceAtaCor Medical compliance and trust
Trust signalCompliance2 records
AtaCor Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
AtaCor Medical leadership team
Management profileNumber of profiles
Profiles6 records
AtaCor Medical funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AtaCor Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AtaCor Medical
What does AtaCor Medical do?
AtaCor Medical develops and clinically investigates extravascular implantable cardioverter defibrillator (EV-ICD) lead systems designed to deliver defibrillation, antitachycardia pacing (ATP), and shock therapies without placing hardware inside the heart or vasculature. The company's flagship offering, the Atala EV-ICD Lead System, uses a streamlined parasternal delivery approach and is designed for compatibility with commercially-available transvenous ICDs. The products are currently for investigational use only and are not approved for sale in any geography.
Is AtaCor Medical a public or private company?
AtaCor Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was AtaCor Medical founded?
AtaCor Medical was founded in 2018. It employs 11 to 50 people.
Where is AtaCor Medical based?
AtaCor Medical is headquartered in San Clemente, United States, in the North America region.
How does AtaCor Medical make money?
One revenue line is on record: extravascular ICD Lead System.
Who are AtaCor Medical's main competitors?
Broad incumbents on record are Boston Scientific, Medtronic, BIOTRONIK and MicroPort Scientific. Direct peers are Abbott and Cameron Health (historical). Emerging players are EBR Systems, Imricor Medical Systems, Cala Health and Cardiac Insight.
Does AtaCor Medical have an API?
No public API is recorded for AtaCor Medical.
What industry is AtaCor Medical in?
AtaCor Medical's product category is Cardiac Rhythm Management Devices. Its primary akta.pro industry code is HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT), with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3845.